Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression  

作　　者：Basma M E Mohamed Mohamed E A Abdelrahim 

机构地区：[1]Department of Clinical Pharmacy,Faculty of Pharmacy,Beni-Suef University,Beni-Suef 343433,Egypt

出　　处：《World Journal of Clinical Cases》2024年第32期6538-6542,共5页世界临床病例杂志（英文）

摘　　要：In this editorial,we comment on the article by Lei et al,with a specific focus on the timing of the initiation of the antifibrotic agent pirfenidone(PFD)in the management of idiopathic pulmonary fibrosis(IPF)and its impact on lung function of IPF patients.PFD is an antifibrotic agent that is widely used in the management of IPF in both early and advanced stages.It inhibits various pathways and has antifibrotic,anti-inflammatory,and antioxidant properties.Despite dosage lowering,PFD slowed IPF progression and maintained functional capacity.The 6-min walk distance test indicated that patients tolerated adverse events well,and PFD significantly reduced the incidence of progression episodes and death.Even when a single disease-progression event occurred,continuing PFD treatment had benefits.

关 键 词：Idiopathic pulmonary fibrosis Pirfenidone Pirfenidone anti-inflammatory mechanism Pirfenidone antifibrotic activity Timing impact 

分 类 号：R593.2[医药卫生—内科学]